Why AMRI Is Actually Getting A Very Good Premium
Shares of Albany Molecular Research Inc. (NASDAQ: AMRI) saw a handy gain on Tuesday after it was announced that the company signed a definitive agreement to be acquired by Carlyle Group and GTCR. Although the price only represents about a 9% from Monday’s closing price, it is actually much more than that considering the stock’s recent trading history.